The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

4 months ago

Version History

1 additional source confirmed this story

Version 14 months ago

What changed: Clarified that the system previously held clearance for spine procedures and added positive analyst sentiment from Zacks regarding growth and stock performance.

StocksMediumUpdated•Originally published 30 March 2026•Updated 1 April 2026•

1 min read

Medtronic Secures FDA Clearance for AI-Driven Stealth AXiS Surgical System

Key Facts

1Medtronic received FDA 510(k) clearance for its Stealth AXiS surgical system for use in cranial and ear, nose, and throat (ENT) procedures.

2The system utilizes AI-enabled tractography for brain mapping to enhance surgical planning and navigation.

3Medtronic is targeting a larger share of the 15 billion USD cranial and spinal technologies market.

Medtronic (MDT) has received FDA 510(k) clearance for its Stealth AXiS surgical system, expanding its application to include cranial and ear, nose, and throat (ENT) procedures. This regulatory expansion follows a previous clearance for spine procedures, significantly broadening the system's clinical utility. The platform integrates advanced robotics with AI-enabled tractography to provide high-precision brain mapping and surgical navigation. This move allows Medtronic to further penetrate the cranial and spinal technologies market, currently valued at approximately 15 billion USD. Analysts at Zacks expect this approval to boost the company's growth prospects and potentially drive gains in MDT stock. Medtronic continues to focus on integrating digital solutions into its surgical portfolio to solidify its leadership in the high-margin medical technology sector.

Sources:

MedTech Dive

zacks.com